Mobile Clinic Services for Women Who Inject Drugs

Recruiting in Palo Alto (17 mi)

Overseen byMaria Corcorran, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Washington

No Placebo Group

Trial Summary

What is the purpose of this trial?The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle. The pop-up clinic will be housed within a van and serve as a research extension of the SHE Clinic, a Harborview Medical Center run clinic for women who exchange sex and use drugs in north Seattle. Through the implementation of the pop-up clinic, the investigators will aim to assess: 1. The impact of the pop-up clinic on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) among WWID. 2. The impact of point of care (POC) sexually transmitted infection (STI) testing on STI treatment completion rates. 3. The acceptability and feasibility of providing HIV prevention care for WWID and exchange sex in a pop-up van clinic.

Eligibility Criteria

This trial is for women over 18 who inject drugs and are not known to have HIV. Participants must be willing to give informed consent, identify as female, and have a history of drug injection.

Inclusion Criteria

Ever injected drugs

I identify as female.

Willing and able to provide informed consent to participate in the study

+2 more

Exclusion Criteria

Living with HIV

Never injected drugs

I am under 18 years old.

+2 more

Participant Groups

The study tests the effectiveness of a mobile van clinic in increasing the use of HIV prevention medication (PrEP) and treatments for opioid addiction among women who inject drugs. It also evaluates on-site STI testing's impact on treatment completion rates.

1Treatment groups

Experimental Treatment

Group I: Study cohortExperimental Treatment1 Intervention

The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months. The investigators will assess uptake of PrEP and buprenorphine; POC STI testing and treatment completion rates; sustained use of PrEP and buprenorphine at months 3 and 6 (n=50). The investigators will conduct surveys to assess and characterize the acceptability and feasibility of venue-based primary and HIV prevention care among women who inject drugs (WWID).